Premium
Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24‐Week Patient‐Reported Outcome Results of a Phase III, Multicenter Study
Author(s) -
Gladman D.,
Fleischmann R.,
Coteur G.,
Woltering F.,
Mease P. J.
Publication year - 2014
Publication title -
arthritis care and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.032
H-Index - 163
eISSN - 2151-4658
pISSN - 2151-464X
DOI - 10.1002/acr.22256
Subject(s) - certolizumab pegol , medicine , psoriatic arthritis , dermatology life quality index , placebo , visual analogue scale , population , tnf inhibitor , tolerability , quality of life (healthcare) , randomized controlled trial , physical therapy , arthritis , etanercept , adverse effect , disease , rheumatoid arthritis , pathology , alternative medicine , nursing , environmental health
Objective To examine the effect of certolizumab pegol (CZP) on patient‐reported outcomes (PROs) in psoriatic arthritis (PsA) patients with and without prior tumor necrosis factor (TNF) inhibitor exposure. Methods The ongoing phase III RAPID‐PsA trial was double blind and placebo controlled to week 24. Patients were randomized 1:1:1 to placebo every 2 weeks or CZP 400 mg at weeks 0, 2, and 4, followed by either CZP 200 mg every 2 weeks or CZP 400 mg every 4 weeks. PRO measures evaluated were the Health Assessment Questionnaire (HAQ) disability index (DI), health status (measured by the Short Form 36 [SF‐36] health survey), Psoriatic Arthritis Quality of Life (PsAQOL), Fatigue Assessment Scale, patient assessment of pain (visual analog scale), and Dermatology Life Quality Index (DLQI). Post hoc analyses of PROs in patients with and without prior TNF inhibitor exposure were conducted. Change from baseline for all PROs was analyzed for the randomized population using analysis of covariance with last observation carried forward imputation. Results A total of 409 patients were randomized. Twenty percent had received a prior TNF inhibitor. Baseline demographics were similar between the treatment groups. At week 24, clinically meaningful differences in HAQ DI, SF‐36, PsAQOL, fatigue, pain, and DLQI were observed in both CZP arms versus placebo ( P < 0.001), irrespective of prior TNF inhibitor exposure. More CZP‐treated patients reached SF‐36 general population norms than placebo‐treated patients. Conclusion Both CZP dosing schedules provided rapid improvements in PROs across multiple disease aspects in patients with PsA. The benefits of CZP treatment for health‐related quality of life were seen across generic, PsA‐specific, and dermatology‐specific measures and were observed in patients regardless of prior TNF inhibitor exposure.